Elevance Health, Inc. (ELV)
(Delayed Data from NYSE)
$405.76 USD
-5.00 (-1.22%)
Updated Oct 31, 2024 04:00 PM ET
After-Market: $405.76 0.00 (0.00%) 6:54 PM ET
5-Strong Sell of 5 5
B Value B Growth C Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$405.76 USD
-5.00 (-1.22%)
Updated Oct 31, 2024 04:00 PM ET
After-Market: $405.76 0.00 (0.00%) 6:54 PM ET
5-Strong Sell of 5 5
B Value B Growth C Momentum B VGM
Zacks News
Is a Surprise Coming for Elevance (ELV) This Earnings Season?
by Kaibalya Pravo Dey
Elevance (ELV) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
5 Giants Likely to Win Big on Earnings Results This Week
by Nalak Das
We have narrowed our search to five large-cap stocks that are poised to beat on earnings results this week. These are: NFLX, ISRG, ELV, EFX, CSX.
Elevance Health (ELV), CD&R to Unveil Primary Care Offering
by Zacks Equity Research
Elevance Health (ELV) forms an alliance with CD&R to enhance primary care delivery by making collective use of the partners' assets and subsequently, reduce overall costs of care.
The Zacks Analyst Blog Highlights Microsoft, Novo Nordisk, United Parcel Service, Booking and Elevance Health
by Zacks Equity Research
Microsoft, Novo Nordisk, United Parcel Service, Booking and Elevance Health are included in this Analyst Blog.
Will Elevance (ELV) Beat Q1 Earnings on Carelon Strength?
by Zacks Equity Research
The first-quarter results of Elevance (ELV) are likely to reflect higher product revenues and Commercial Individual membership growth.
Top Analyst Reports for Microsoft, Novo Nordisk & United Parcel
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Microsoft Corporation (MSFT), Novo Nordisk A/S (NVO) and United Parcel Service, Inc. (UPS).
Medpace (MEDP) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Medpace (MEDP) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Elevance Health (ELV) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Elevance Health (ELV) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Elevance Health (ELV) Brand Inks Deal to Better Serve Georgia
by Zacks Equity Research
Elevance Health's (ELV) brand, Anthem Blue Cross and Blue Shield, collaborates to make the benefits of Piedmont's healthcare network available to its members across specific Georgia regions.
ELV vs. GDRX: Which Stock Is the Better Value Option?
by Zacks Equity Research
ELV vs. GDRX: Which Stock Is the Better Value Option?
Why Elevance Health (ELV) is Poised to Beat Earnings Estimates Again
by Zacks Equity Research
Elevance Health (ELV) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
How to Find Strong Medical Stocks Slated for Positive Earnings Surprises
by Zacks Equity Research
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
Wall Street Set to See a Broad-Based Rally in Q2: 5 Picks
by Nalak Das
It will be prudent to invest in non-technology stocks with a favorable Zacks Rank to gain in the near future. Five such stocks are: WELL, GIS, ELV, RCL, RYAAY.
Health Insurance Stocks Drop: Insights Into the Late Monday Fall
by Kaibalya Pravo Dey
Higher costs and lower hikes in rates can lead to lower profit growth, which concerns investors.
Should You Invest in the iShares U.S. Healthcare Providers ETF (IHF)?
by Zacks Equity Research
Sector ETF report for IHF
Elevance Health (ELV) Dips More Than Broader Market: What You Should Know
by Zacks Equity Research
In the latest trading session, Elevance Health (ELV) closed at $513.85, marking a -0.16% move from the previous day.
ELV or GDRX: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
ELV vs. GDRX: Which Stock Is the Better Value Option?
Humana (HUM), DUOS Unveil Program to Improve Veterans' Health
by Zacks Equity Research
Humana (HUM) collaborates with DUOS to develop a program that aims to provide personalized care and assure the well-being of Louisiana's Veteran community, who have a HUM MA plan and suffer from chronic conditions.
Sera Prognostics, Inc. (SERA) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
Sera Prognostics (SERA) delivered earnings and revenue surprises of 0% and 56.84%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
HealthEquity (HQY) Q4 Earnings Surpass Estimates, Margins Up
by Zacks Equity Research
HealthEquity (HQY) witnesses solid growth in HSAs, besides recording robust performances in the majority of its segments, in the fourth quarter of fiscal 2024.
3 Stocks to Buy for Decreased Volatility
by Derek Lewis
For those seeking a more conservative approach, low-beta stocks are common targets. Interestingly enough, analysts have recently become bullish on these three.
HealthEquity (HQY) Beats Q4 Earnings and Revenue Estimates
by Zacks Equity Research
HealthEquity (HQY) delivered earnings and revenue surprises of 12.50% and 1.48%, respectively, for the quarter ended January 2024. Do the numbers hold clues to what lies ahead for the stock?
Cencora (COR) Hits 52-Week High: What's Driving the Stock?
by Zacks Equity Research
Investors are optimistic about Cencora's (COR) strength in the U.S. Healthcare Solutions business.
Why Elevance (ELV) is a Smart Addition to Your Portfolio Now
by Zacks Equity Research
Elevance's (ELV) top line is poised to gain from rising product revenues, administrative fees and other revenues.
Elevance Health (ELV) Ascends While Market Falls: Some Facts to Note
by Zacks Equity Research
The latest trading day saw Elevance Health (ELV) settling at $510.57, representing a +0.21% change from its previous close.